SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Phase 1 dose-optimization data are expected in Q3 2026 to support initiation of a Phase 2 proof-of-concept program in ADPKD in Q4 2026. The update suggests progress in the clinical timeline, with timing visibility improving for the next development step.

Analysis

Phase 1 dose-optimization data are expected in Q3 2026 to support initiation of a Phase 2 proof-of-concept program in ADPKD in Q4 2026. The update suggests progress in the clinical timeline, with timing visibility improving for the next development step.